Fate Therapeutics, Inc. (FATE)

Market Cap	103.49M
Revenue (ttm)	13.63M
Net Income (ttm)	-186.26M
Shares Out	114.60M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,698,233
Open	0.950
Previous Close	0.941
Day's Range	0.892 - 0.949
52-Week Range	0.870 - 7.650
Beta	2.26
Analysts	Hold
Price Target	5.50 (+509.01%)
Earnings Date	Mar 5, 2025

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2013
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: FATE
• Website: https://www.fatetherapeutics.com

Financial Performance

In 2024, Fate Therapeutics's revenue was $13.63 million, a decrease of -78.55% compared to the previous year's $63.53 million. Losses were -$186.26 million, 15.7% more than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for FATE stock is "Hold." The 12-month stock price forecast is $5.5, which is an increase of 509.01% from the latest price.

Price Target

$5.5

(509.01% upside)

Analyst Consensus: Hold